{
  "names": ["TAK-591"],
  "company": "Takeda",
  "genes": ["AGTR"],
  "clinical_annotation": [
    "AGTR1: Thiazides, Ace Inhibitors toxicity; losartan, Ace Inhibitors, candesartan, perindopril, captopril, angiotensin II, irbesartan, nitrendipine efficacy; atorvastatin metabolism",
    "AGTR2: ACE Inhibitor Pathway, Renin-angiotensin-aldosterone system"
  ],
  "pathway_annotation": [
    "AGTR1: ACE Inhibitor Pathway, Renin-angiotensin-aldosterone system, Losartan Pathway",
    "AGTR2: ACE Inhibitor Pathway, Renin-angiotensin-aldosterone system"
  ],
  "diseases": [
    "AGTR1: Left ventricular hypertrophy",
    "Ischemia",
    "Liver cirrhosis",
    "Essential hypertension",
    "Covid-19",
    "Heart failure",
    "Myocardial infarction",
    "Diabetes mellitus",
    "Type 2 diabetes mellitus",
    "Coronary artery disease",
    "Hypertension"
  ],
  "targets": [
    {
      "names": ["Angiotensin receptor"]
    }
  ],
  "mechanism_of_action": ["Angiotensin receptor antagonists"],
  "indications": ["Hypertension"],
  "indication_type": "Cardiovascular",
  "phase": 1,
  "year_discontinued": 2011,
  "discontinuation_reason": "TAK-536 was launched/ no need to keep TAK-591",
  "link": "https://www.takeda.com/4ab325/siteassets/system/investors/quarterly-announcements/fy2012/qr2012_full_d_en.pdf",
  "repurposed_efforts": [
    "Idiopathic Intracranial Hypertension",
    "Iatrogenic Cushing's Disease"
  ],
  "repurposed_drug_name": "AZD4017",
  "repurposed_indications": ["Iatrogenic Cushing's Disease"],
  "repurposed_year": 2016,
  "repurposed_company": "AstraZeneca",
  "repurposed_phase": 2
}
